Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

is being developed to treat muscle atrophy that sometimes comes with weight loss drugs like Zepbound. Elsewhere, it is ...

The global weight loss and obesity management market is set to experience remarkable expansion in the coming decade. With new ...

More than 800 million adults have diabetes worldwide – almost twice as many as previous estimates have suggested – and more than half of those aged over 30 who have the condition are not receiving ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...